Abbmira Therapeutics
Basel, Switzerland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Abbmira Therapeutics AG is a Swiss biotech company founded in 2021, based in Basel, focused on revolutionizing cancer treatment. The company develops first-in-class small molecule immunomodulatory drugs designed to reprogram tumor-associated macrophages (TAMs) to overcome immune evasion. Its lead candidate, Compound42, aims to reshape the tumor microenvironment to drive durable anti-cancer immune responses.
Small Molecules